Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development

QR Code

Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development

Bibliographic Details
Main Author:	Falasca, Marco
Format:	Journal Article
Published:	2011
Online Access:	http://hdl.handle.net/20.500.11937/38301

Similar Items

Class II Phosphoinositide 3-Kinases as Novel Drug Targets
by: Falasca, Marco, et al.
Published: (2017)

Regulation and cellular functions of class II phosphoinositide 3-kinases
by: Falasca, Marco, et al.
Published: (2012)

Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms
by: Fyffe, C., et al.
Published: (2013)

New insight into the intracellular roles of class II phosphoinositide 3-kinases
by: Maffucci, T., et al.
Published: (2014)

Targeting phosphoinositide 3-kinase pathways in pancreatic cancer - from molecular signalling to clinical trials
by: Falasca, Marco, et al.
Published: (2011)

Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway
by: Edling, C., et al.
Published: (2014)

3-phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer
by: Fyffe, C., et al.
Published: (2013)

Elucidation of the WNT & AKT/Phosphoinositide-3-Kinase Pathways in Colorectal Carcinoma
by: Khor, Tin Oo
Published: (2004)

Novel roles for class II Phosphoinositide 3-Kinase C2ß in signalling pathways involved in prostate cancer cell invasion.
by: Mavrommati, I., et al.
Published: (2016)

Investigating the mechanisms of activation and action of phosphoinositide 3-kinase C2 alpha in pancreatic beta cells
by: Mazza, S., et al.
Published: (2013)

A phosphoinositide 3-kinase/phospholipase cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation
by: Maffucci, T., et al.
Published: (2009)

Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis
by: Tibolla, G., et al.
Published: (2013)

Key role of phosphoinositide 3-kinase class IB in pancreatic cancer
by: Edling, C., et al.
Published: (2010)

Class II phosphoinositide 3-kinase C2ß regulates a novel signaling pathway involved in breast cancer progression.
by: Chikh, A., et al.
Published: (2016)

Analysis, regulation, and roles of endosomal phosphoinositides
by: Maffucci, T., et al.
Published: (2014)

THE CLASS II PHOSPHOINOSITIDE 3-KINASE ISOFORM beta REGULATES PLATELET FUNCTION AND ARTERIAL THROMBOSIS IN MICE
by: Tibolla, G., et al.
Published: (2011)

Phosphoinositides signalling in cancer: Focus on PI3K and PLC
by: Raimondi, C., et al.
Published: (2012)

Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic ß cells
by: Dominguez, V., et al.
Published: (2011)

Cudraflavone C induces tumor-specific apoptosis in colorectal cancer cells through inhibition of the phosphoinositide 3-kinase (PI3K)-AKT pathway
by: Castresana, Javier S., et al.
Published: (2017)

Yeast Glycogen Synthase Kinase-3 Pathway Inhibitors from an Organic Extract of Streptomyces sp.
by: Cheenpracha, Sarot, et al.
Published: (2009)

An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)

Functional association of phosphoinositide-3-kinase with platelet glycoprotein Iba, the major ligand-binding subunit of the glycoprotein Ib-IX-V complex
by: Mu, F., et al.
Published: (2010)

Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)

Sec14 like PITPs couple lipid metabolism with phosphoinositide synthesis to regulate golgi functionality
by: Mousley, Carl, et al.
Published: (2015)

Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview
by: Fischer, Peter M.
Published: (2017)

Pharmacology classification of drugs
by: Saxena, Anil Kumar
Published: (2012)

Lysophosphatidylinositol Signalling and Metabolic Diseases
by: Arifin, S., et al.
Published: (2016)

The safety pharmacology of Syk inhibitors: new preclinical screens to characterise cardiovascular adverse drug effects
by: Van Daele, Marieke
Published: (2024)

Akt/protein kinase B in skeletal muscle physiology and pathology
by: Wu, M., et al.
Published: (2011)

Investigational ABC transporter inhibitors
by: Falasca, Marco, et al.
Published: (2012)

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
by: Falasca, Marco, et al.
Published: (2010)

Clinical Pharmacology Of Antimalarial Drugs.
Published: (1989)

Kinase targets in CNS drug discovery
by: Gunosewoyo, Hendra, et al.
Published: (2017)

Lysophosphatidylinositol signalling and metabolic diseases
by: Ahmad Arifin, Syamsul, et al.
Published: (2016)

Characterization of Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Stimulators of Steroidogenesis
by: Gunosewoyo, Hendra, et al.
Published: (2013)

Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development
by: Hua, Y., et al.
Published: (2017)

Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)

PITPs as targets for selectively interfering with phosphoinositide signaling in cells
by: Nile, A., et al.
Published: (2014)

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
by: Danic, M., et al.
Published: (2018)

Evaluation of transcriptional cyclin dependent kinase inhibitors as potential cancer therapeutics
by: Liu, Xiangrui
Published: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r34o9fb5ptfp8p9i78ku5p78h1